6589 |
北城證券研發部提供 非經同意不得轉載 本刊內容僅供參考 投資人應謹慎考量投資風險 本公司不負任何法律責任 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6589 台康生技 |
實收資本額 |
3062 (百萬) |
|
|
|
|
|
|
|
|
|
市 場
別 |
OTC |
上 櫃 日 期 |
2019/06/28 |
|
|
|
|
|
|
|
|
|
發 言
人 |
劉理成 |
電 話 |
(02)7708-0123 |
|
|
|
|
|
|
|
|
|
地 址 |
新北市汐止區康寧街169巷101號 |
|
|
|
|
|
|
|
|
|
產 業
別 |
傳產-生技 |
|
|
|
|
|
|
|
|
|
主要產品 |
生物相似藥及新藥研發、生技藥品委託開發暨生產服務(CDMO) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025/5/2 股價 |
63.40 |
法人買賣超合計(近一日) |
買超 19 張 |
|
|
|
|
|
|
|
|
|
2025/5/2
漲跌 |
-0.10
|
法人買賣超合計(近一週) |
買超
515.58 張 |
|
|
|
|
|
|
|
|
|
2025/5/2
漲跌幅 |
-0.16
|
法人買賣超合計(近一月) |
買超
1932.48 張 |
|
|
|
|
|
|
|
|
|
券 資 比 |
0.00
|
外資連8買 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
最新股利發放 |
股東會日期 |
現金股利(元) |
股票股利(元) |
除權日 |
除息日 |
殖利率 |
|
|
|
|
|
|
|
2023/05/31 |
#N/A |
#N/A |
#N/A |
#N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
股利年度 |
股東會日期 |
現金股利(元) |
股票股利(元) |
除權日 |
除息日 |
扣抵率(%) |
殖利率 |
股利殖利率 |
現金殖利率 |
|
|
|
|
2024 |
2025/06/27 |
0.00 |
0.00 |
|
|
|
0% |
0% |
0% |
|
|
|
|
2023 |
2024/05/30 |
0.00 |
0.00 |
|
|
|
0% |
0% |
0% |
|
|
|
|
2022 |
2023/05/31 |
0.00 |
0.00 |
|
|
|
0% |
0% |
0% |
|
|
|
|
2021 |
2022/06/10 |
0.00 |
0.00 |
|
|
|
0% |
0% |
0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
機構估稅後EPS |
-2.28 |
K(9) |
72.32 |
|
技術面 |
技術面 |
基本面 |
基本面 |
籌碼面 |
|
|
|
|
淨值(元) |
30.31 |
D(9) |
66.45 |
評分表 |
(短線) |
(中長線) |
(安全性) |
(成長性) |
|
|
|
|
預估本益比 |
-27.81 |
周K(9) |
33.3 |
|
1.6 |
1.2 |
0.8 |
0.4 |
0.5 |
|
|
|
|
股價淨值比 |
2.09 |
周D(9) |
32.65 |
綜合評分: |
4.5 |
建議: |
觀望 |
目標價: |
78.32 |
|
|
|
|
月線乖離率 |
2.37 |
季線乖離率 |
-13.21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2025/4/2 |
2025/4/11 |
2025/4/18 |
2025/4/25 |
2025/5/2 |
20*PE |
|
3*PB |
90.57 |
|
|
|
|
股價 |
72.10 |
60.50 |
63.00 |
61.30 |
63.40 |
15*PE |
|
2*PB |
60.38 |
|
|
|
|
成交量(千股) |
1,032 |
4,178 |
1,485 |
1,199 |
1,336 |
10*PE |
|
1*PB |
30.19 |
|
|
|
|
資餘 |
3,513 |
2,652 |
2,644 |
2,578 |
2,569 |
5*PE |
|
0.5*PB |
15.10 |
|
|
|
|
券餘 |
13 |
12 |
7 |
0 |
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
季IFRS財報(損益單季) |
202501 |
202404 |
202403 |
202402 |
202401 |
202304 |
202303 |
202302 |
|
|
|
|
營業收入淨額(千) |
|
294,641
|
248,223
|
246,403
|
219,693
|
456,567
|
211,451
|
138,314
|
|
|
|
|
營業成本(千) |
|
194,555
|
169,432
|
224,186
|
201,802
|
296,130
|
155,926
|
156,325
|
|
|
|
|
營業毛利(千) |
|
100,086
|
78,791
|
22,217
|
17,891
|
160,437
|
55,525
|
-18,011 |
|
|
|
|
營業費用(千) |
|
310,970
|
324,652
|
305,245
|
231,919
|
516,648
|
254,905
|
237,912
|
|
|
|
|
營業利益(千) |
|
-210,884 |
-245,861 |
-283,028 |
-214,028 |
-356,211 |
-199,380 |
-255,923 |
|
|
|
|
營業外收入及支出(千) |
|
93,836
|
-9,835 |
62,842
|
110,453
|
-49,301 |
88,072
|
62,284
|
|
|
|
|
稅前純益(千) |
|
-117,048 |
-255,696 |
-220,186 |
-103,575 |
-405,512 |
-111,308 |
-193,639 |
|
|
|
|
所得稅(千) |
|
546
|
422
|
431
|
440
|
431
|
413
|
418
|
|
|
|
|
稅後純益(千) |
|
-117,594 |
-256,118 |
-220,617 |
-104,015 |
-405,943 |
-111,721 |
-194,057 |
|
|
|
|
其他綜合損益(千) |
|
-6,895 |
-29,671 |
-52,444 |
-3,752 |
33,260
|
7,119
|
39,763
|
|
|
|
|
綜合損益(千) |
|
-124,489 |
-285,789 |
-273,061 |
-107,767 |
-372,683 |
-104,602 |
-154,294 |
|
|
|
|
原始每股稅前盈餘(元) |
|
-0.38 |
-0.84 |
-0.72 |
-0.34 |
-1.32 |
-0.37 |
-0.64 |
|
|
|
|
原始每股稅後盈餘(元) |
|
-0.39 |
-0.84 |
-0.72 |
-0.34 |
-1.33 |
-0.37 |
-0.64 |
|
|
|
|
毛利率(%) |
|
33.97
|
31.74
|
9.02
|
8.14
|
35.14
|
26.26
|
-13.02 |
|
|
|
|
營業利益率(%) |
|
-71.57 |
-99.05 |
-114.86 |
-97.42 |
-78.02 |
-94.29 |
-185.03 |
|
|
|
|
稅後純益率(%) |
|
-39.91 |
-103.18 |
-89.54 |
-47.35 |
-88.91 |
-52.84 |
-140.30 |
|
|
|
|
稅後權益報酬率(%) |
|
-1.26 |
-2.68 |
-2.25 |
-1.04 |
-4.00 |
-1.08 |
-1.86 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
月營收 |
單月營收(千) |
累計營收(千) |
單月MoM |
單月YoY |
累計YoY |
累計稅前EPS |
備註 |
近3月營收(千) |
近3月年成長 |
|
|
|
|
202504 |
0 |
0 |
0.00
|
0.00
|
0.00
|
|
|
0 |
0 |
|
|
|
|
202503 |
89,468 |
181,923 |
111.28
|
53.08
|
-17.19 |
|
|
181,923
|
-17.19 |
|
|
|
|
202502 |
42,346 |
92,455 |
-15.49 |
-10.15 |
-42.66 |
|
創近一年新低 |
230,836
|
-13.68 |
|
|
|
|
202501 |
50,109 |
50,109 |
-63.79 |
-56.09 |
-56.09 |
|
|
284,417
|
-40.33 |
|
|
|
|
202412 |
138,381 |
1,008,960 |
44.26
|
30.33
|
-1.34 |
-2.27 |
創近一年新高 |
294,641
|
-35.47 |
|
|
|
|
202411 |
95,927 |
870,579 |
59.00
|
-62.58 |
-5.01 |
|
|
234,480
|
-46.26 |
|
|
|
|
202410 |
60,333 |
774,652 |
-22.87 |
-35.84 |
17.35
|
|
|
220,023
|
-9.48 |
|
|
|
|
202409 |
78,220 |
714,319 |
-3.99 |
-8.99 |
26.19
|
-1.89 |
|
248,223
|
17.39 |
|
|
|
|
202408 |
81,470 |
636,099 |
-7.98 |
29.14
|
32.48
|
|
|
230,885
|
29.87 |
|
|
|
|
202407 |
88,533 |
554,629 |
45.42
|
41.84
|
32.99
|
|
|
269,780
|
61.32 |
|
|
|
|
202406 |
60,882 |
466,096 |
-49.42 |
16.45
|
31.43
|
-1.06 |
|
246,404
|
78.15 |
|
|
|
|
202405 |
120,365 |
405,214 |
84.73
|
129.11
|
34.02
|
|
|
243,966
|
61.25 |
|
|
|
|
202404 |
65,157 |
284,849 |
11.49
|
94.52
|
14.02
|
|
|
170,732
|
-5.02 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
券商代號 |
券商名稱 |
張增減 |
買張 |
賣張 |
券商代號 |
券商名稱 |
張增減 |
買張 |
賣張 |
|
|
|
|
1650 |
新加坡商瑞銀 |
34 |
48 |
14 |
9600 |
富邦 |
-42 |
8 |
50 |
|
|
|
|
5850 |
統一 |
32 |
32 |
0 |
9A00 |
永豐金 |
-28 |
7 |
35 |
|
|
|
|
8880 |
國泰 |
18 |
24 |
6 |
1470 |
台灣摩根士丹利 |
-27 |
0 |
27 |
|
|
|
|
9800 |
元大 |
17 |
48 |
31 |
9200 |
凱基 |
-14 |
33 |
47 |
|
|
|
|
1440 |
美林 |
17 |
22 |
5 |
8440 |
摩根大通 |
-11 |
7 |
18 |
|
|
|
|
8150 |
台新 |
6 |
6 |
0 |
5920 |
元富 |
-9 |
8 |
17 |
|
|
|
|
7790 |
國票 |
4 |
5 |
1 |
1030 |
土銀 |
-5 |
0 |
5 |
|
|
|
|
5380 |
第一金 |
4 |
5 |
1 |
5660 |
日進 |
-2 |
0 |
2 |
|
|
|
|
5380 |
第一金 |
4 |
5 |
1 |
9300 |
華南永昌 |
-2 |
2 |
4 |
|
|
|
|
6110 |
台中銀 |
3 |
3 |
0 |
7030 |
致和 |
-1 |
0 |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20250407 |
CDMO概念股 也有保命符 |
|
|
|
|
20250407 |
台康乳癌藥 拚墨國上市 |
|
|
|
|
20250303 |
台康 乳癌新藥 跨大步 |
|
|
|
|
20250218 |
證交所董事會通過 台康生技轉申請上市案及兆聯上市申請案 |
|
|
|
|
20250218 |
台康生技、兆聯實業上市案 證交所董事會通過 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
個股TOP15買賣超券商籌碼統計(20日) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1日籌碼集中度 |
-3.8 |
|
10日籌碼集中度 |
12.3 |
優 |
單日買賣超 |
-11 |
|
|
|
5日籌碼集中度 |
11.2 |
|
20日籌碼集中度 |
8.6 |
優 |
累計買賣超 |
-125 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
個股借券統計(20日) |
千張大戶統計(20週) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
單日借賣張數 |
8238 |
借券餘額 |
8532 |
千張大戶戶數 |
26 |
大戶比例 |
52.2 |
|
|
|
|
|
|
|
|
|
|
|
|
更新日期: |
2025/5/2 18:09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|